Table 1.
Antimicrobial Susceptibility of Escherichia coli Urine Isolatesa From the Index Patient and Her Sibling
| Antimicrobial | MIC in mg/L, S/I/R Interpretation |
||||
|---|---|---|---|---|---|
| Index Patient Episode |
Sister |
||||
| Initial | Second (3 wk After Initial) | Third (6 wk After Initial) | Fourth (9 wk After Initial) | (11 wk After Index Initial) | |
| Ampicillin | >16 R | >16 R | >16 R | >16 R | >16 R |
| Ampicillin-sulbactam | 16/8 I | 16/8 I | 16/8 I | 16/8 I | 16/8 I |
| Piperacillin-tazobactam | ≤16/4 S | ≤16/4 S | ≤16/4 S | ≤16/4 S | ≤16/4 S |
| Cefazolin | >16 R | >16 R | >16 R | >16 R | >16 R |
| Cefdinir | >2 R | >2 R | >2 R | >2 R | >2 R |
| Cefepime | 8 S | >16 R | 8 S | 8 S | 8 S |
| Ceftriaxone | >32 R | >32 R | >32 R | >32 R | >32 R |
| Cephalothin | >16 R | >16 R | >16 R | >16 R | >16 R |
| Ertapenem | ≤0.25 S | ≤0.25 S | ≤0.25 S | ≤0.25 S | ≤0.25 S |
| Meropenem | ≤1 S | ≤1 S | ≤1 S | ≤1 S | ≤1 S |
| Ciprofloxacin | >2 R | >2 R | >2 R | >2 R | >2 R |
| Levofloxacin | >4 R | >4 R | >4 R | >4 R | >4 R |
| Amikacin | ≤8 S | ≤8 S | ≤8 S | ≤8 S | ≤8 S |
| Gentamicin | >8 R | >8 R | >8 R | >8 R | >8 R |
| Tobramycin | 8 I | 8 I | 8 I | 8 I | 8 I |
| Nitrofurantoin | ≤32 S | ≤32 S | ≤32 S | ≤32 S | ≤32 S |
| TMP-SMX | >2/38 R | ≤0.5/9.5 S | >2/38 R | >2/38 R | >2/38 R |
| Fosfomycin | 128 I | ≤64 S | ≤64 S | ≤64 S | ≤64 S |
Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, susceptible; TMP-SMX, trimethoprim-sulfamethoxazole.
a All specimens were obtained by sterile in-and-out catheterization. Susceptibility testing was performed by the clinical microbiology laboratory using agar dilution.